PMID- 15332692
OWN - NLM
STAT- MEDLINE
DCOM- 20041019
LR  - 20190222
IS  - 1079-2082 (Print)
IS  - 1079-2082 (Linking)
VI  - 61
IP  - 14
DP  - 2004 Jul 15
TI  - Omalizumab: a recombinant humanized anti-IgE antibody for allergic asthma.
PG  - 1449-59
AB  - PURPOSE: The pharmacology, efficacy, dosage, adverse events, and economics of 
      omalizumab are discussed. SUMMARY: Omalizumab, a recombinant DNA-derived 
      humanized monoclonal antibody, binds to the C epsilon3 domain of immunoglobulin E 
      (IgE) and forms complexes that inhibit the immune system's response to allergens 
      by averting IgE-mediated inflammatory changes. Omalizumab exhibits a similar 
      pharmacokinetic profile in adults, adolescents, and children. Omalizumab is 
      indicated for adults and adolescents with moderate to severe persistent asthma 
      who have a positive skin test or in vitro reactivity to a perennial aeroallergen 
      and whose symptoms are inadequately controlled with inhaled corticosteroids. 
      Because of the limited data regarding the safety and effectiveness of omalizumab 
      in children, the drug is indicated for patients 12 years of age or older. The 
      recommended starting dosage is 150-375 mg s.c. every two or four weeks. Dosages 
      and frequency of dose administration are determined by total serum IgE level, 
      measured before the start of treatment, and body weight. Omalizumab is generally 
      well tolerated in adults and children with allergic asthma. Adverse events most 
      commonly observed are injection-site reaction, viral infection, 
      upper-respiratory-tract infection, sinusitis, headache, and pharyngitis. Three 
      large phase III clinical trials demonstrated that omalizumab is more effective 
      than placebo in controlling moderate to severe allergic asthma in patients who 
      have poor disease control or exacerbations despite recommended therapy. 
      Currently, there are no clinical comparisons of omalizumab with other standard 
      treatments for asthma; therefore, it is difficult to determine its overall place 
      in therapy. CONCLUSION: Omalizumab should be considered as a second-line therapy 
      for patients with moderate to severe persistent allergic asthma.
FAU - Ruffin, Charnelda G
AU  - Ruffin CG
AD  - ACS State Healthcare, Atlanta, USA. charnelda.g.ruffin@kp.org
FAU - Busch, Benita E
AU  - Busch BE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Anti-Idiotypic
MH  - *Antibodies, Monoclonal/metabolism/pharmacokinetics/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - *Asthma/classification/drug therapy/economics
MH  - Biological Availability
MH  - Child
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Omalizumab
MH  - Randomized Controlled Trials as Topic
MH  - Severity of Illness Index
RF  - 46
EDAT- 2004/08/31 05:00
MHDA- 2004/10/20 09:00
CRDT- 2004/08/31 05:00
PHST- 2004/08/31 05:00 [pubmed]
PHST- 2004/10/20 09:00 [medline]
PHST- 2004/08/31 05:00 [entrez]
AID - 10.1093/ajhp/61.14.1449 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2004 Jul 15;61(14):1449-59. doi: 10.1093/ajhp/61.14.1449.